Cancer Home > Cometriq Dosage
Cometriq is a chemotherapy drug that comes as a capsule and is taken once daily. The recommended Cometriq dosage will depend on how well you tolerate the medicine and other medications you are taking, among other factors. The usual recommended amount for treating medullary thyroid cancer is 140 mg a day. You may need a lower amount if you develop serious side effects.
The dose of Cometriq™ (cabozantinib) your healthcare provider recommends will vary, depending on a number of factors, including:
- How you tolerate the medicine
- Other medications you are taking.
As is always the case, do not adjust your dosage unless your healthcare provider specifically tells you to do so.
The usual recommended dose of Cometriq for the treatment of medullary thyroid cancer (a rare type of thyroid cancer) is 140 mg a day. Treatment normally continues until the cancer progresses or the medication is no longer tolerated because of potentially dangerous or particularly bothersome side effects.
Your healthcare provider may recommend you stop the drug, at least temporarily, if you develop certain side effects. If you are restarted on Cometriq after the side effect improves, you will likely be given a lower dosage.
Doses are usually decreased by 40 mg after each side effect that causes treatment interruption. For example, if you were taking Cometriq 140 mg a day before developing the side effect, you will be restarted on Cometriq 100 mg a day. The lowest recommended dose is 60 mg a day.
If you cannot tolerate a 60-mg daily dosage, your healthcare provider may recommend you stop treatment altogether. In addition, people who develop certain potentially dangerous side effects, such as a heart attack or stroke, should generally stop Cometriq and not take it again.
People who take certain other medications may be treated with lower or higher Cometriq doses (see Cometriq Drug Interactions). The highest recommended dose is 180 mg a day.
This drug is generally not recommended for use in people with moderate-to-severe liver disease.